natgillin/translations-raw huggingface dataset:
Tablet core: povidone, pregelatinized starch (maize), poloxamer 188, microcrystalline cellulose, croscarmellose sodium, colloidal hydrated silica and magnesium stearate.
Jezgra tablete: povidon, prethodno geliran kukuruzni škrob, poloksamer 188, mikrokristalična celuloza, umrežena karmelozanatrij, koloidni hidratizirani silicijev dioksid i magnezijev stearat.
Tablet core: pregelatinized starch (maize), magnesium stearate, povidone (K30), colloidal anhydrous silica and microcrystalline cellulose, silicified.
Jezgra tablete: prethodno geliran škrob (kukuruzni), magnezijev stearat, povidon (K30), koloidni, bezvodni silicijev dioksid i mikrokristalična celuloza, silicirana
Tablet core; Calcium hydrogen phosphate anhydrous, croscarmellose sodium, povidone, magnesium stearate.
Jezgra tablete; bezvodni kalcijev hidrogen fosfat; umrežena karmeloza natij; povidon; magnezijev stearat.
tablet core; microcrystalline cellulose, sodium starch glycollate (gluten free), magnesium stearate, colloidal silicon dioxide tablet film-coat; hypromellose, titanium dioxide, macrogol 400 and polysorbate 80.
jezgra tablete; mikrokristalična celuloza, natrijev škroboglikolat (bez glutena), magnezijev stearat, koloidni silicijev dioksid ovojnica tablete; hipromeloza, titanijev dioksid, makrogol 400, polisorbat 80.
Tablet cores for 5/10/15/20 mg film-coated tablets
Jezgra tablete za filmom obložene tablete od 5/10/15/20 mg
Tablet cores for 5/10/15/20 mg film-coated tablets Lactose monohydrate
Jezgre tableta za 5/10/15/20 mg filmom obložene tablete laktoza hidrat
Tablet cores for 5/10/15/20 mg film-coated tablets:
Jezgre tableta za 5 mg/10 mg/15 mg/20 mg filmom obložene tablete:
Tablet cores for 5/10/15/20 mg film-coated tablets: Microcrystalline cellulose
Jezgre tableta za 5 mg/10 mg/15 mg/20 mg filmom obložene tablete: celuloza, mikrokristalična
Tablet film coat Hypromellose Titanium dioxide Macrogol 400
Film ovojnica tablete hipromeloza titanijev dioksid makrogol 400
Tablet film coat Titanium dioxide (E171) Macrogol
Ovojnica tablete Titanijev dioksid (E171) Makrogol
Tablet film coat: Hypromellose (E464), titanium dioxide (E171), macrogol 400, polysorbate 80
Film ovojnica tablete: hipromeloza (E464) titanijev dioksid (E171) makrogol 400 polisorbat 80
Tablet film coat: Hypromellose, titanium dioxide (E171), macrogol, polysorbate 80, iron oxide yellow (E172), iron oxide black (E172)
Film- ovojnica: hipromeloza, titaniijev dioksid (E171), makrogol, polisorbat 80, žuti željezov oksid (E172), crni željezov oksid (E172)
Tablet film coat: Hypromellose, titanium dioxide (E171), macrogol, polysorbate 80, iron oxide yellow (E172), iron oxide black (E172)
Film- ovojnica: hipromeloza, titanijev dioksid (E171), makrogol, polisorbat 80, žuti željezov oksid (E172), crni željezov oksid (E172)
Tablet film coat: Hypromellose, titanium dioxide (E171), macrogol, polysorbate 80, iron oxide yellow (E172), iron oxide red (E172).
Film- ovojnica tablete: hipromeloza, titanijev dioksid (E171), makrogol, polisorbat 80, žuti željezov oksid (E172), crveni željezov oksid (E172).
Tablet film coat: macrogol 3350, hypromellose, titanium dioxide (E 171), iron oxide red (E 172).
Film-ovojnica tablete: makrogol 3350, hipromeloza, titanijev dioksid (E171), crveni željezov oksid (E172).
Tablet film coat: macrogol 3350, hypromellose, titanium dioxide (E 171), iron oxide yellow (E 172).
Film ovojnica tablete: makrogol 3350, hipromeloza, titanijev dioksid (E 171), žuti željezov oksid (E 172).
Tablet film-coat Hypromellose 3cP Hypromellose 6cP Polysorbate 80
Film ovojnica tablete hipromeloza 3cP hipromeloza 6cP polisorbat 80
Tablet film-coat polyvinyl alcohol, macrogol, talc, titanium dioxide (E171), iron oxide yellow (E172)
Film ovojnica tablete polivinilni alkohol, makrogol, talk, titanijev dioksid (E171), željezov oksid, žuti (E172)
Tablet film-coat: Hypromellose (E464), Titanium dioxide (E171), Black iron oxide (E172), Macrogol, Polysorbate 80
Film ovojnica tablete: hipromeloza (E464), titanijev dioksid (E171), željezov oksid, crni (E172), makrogol, polisorbat 80
Tablet film-coat: Hypromellose 3cP, hypromellose 6cP, polysorbate 80, macrogol 400, titanium dioxide E171.
Ovojnica tablete: Hipromeloza 3cP, hipromeloza 6cP, polisorbat 80, makrogol 400, titanijev dioksid E171.
Tablet film-coating: hypromellose (E464), titanium dioxide (E171), macrogol 400, iron oxide black (E172) and iron oxide red (E172).
Film ovojnica tablete: hipromeloza (E464), titanijev dioksid (E171), makrogol 400, crni željezov oksid (E172) i crveni željezov oksid (E172).
Tablet film-coating: hypromellose (E464), titanium dioxide (E171), talc, macrogol 400, and iron oxide yellow (E172).
Film ovojnica tablete: hipromeloza (E464), titanijev dioksid (E171), talk, makrogol 400 i žuti željezov oksid (E172).
Tablet film-coating: polyvinyl alcohol (E1203), polyethylene glycol 3350, talc (E553b), titanium dioxide (E171) and red iron oxide (E172).
Film ovojnica tablete: poli(vinilni alkohol) (E1203), polietilenglikol 3350, talk (E553b), titanijev dioksid (E171) i crveni željezov oksid (E172).
tablet Oprymea 0.18 mg three times a day tablets Oprymea 0.088 mg three times a day tablet Oprymea 0.35 mg three times a day tablets Oprymea 0.18 mg three times a day
tableta Oprymea 0,18 mg tri puta dnevno tablete Oprymea 0,088 mg tri puta dnevno tableta Oprymea 0,35 mg tri puta dnevno tablete Oprymea 0,18 mg tri puta dnevno
Tablet or Oral suspension
Tablete ili oralna suspenzija
Tablet SIFROL 0.088 mg tablets
Tableta SIFROL 0,088 mg tablete
tablet SIFROL 0.18 mg OR tablets SIFROL tablet SIFROL 0.35 mg OR tablets SIFROL 0.18 mg OR
tableta SIFROL 0,18 mg tablete SIFROL 0,088 mg tableta SIFROL 0,35 mg tablete SIFROL 0,18 mg
TABLET STRENGTH
JAČINA TABLETE
Tablet-taking has to start on day 1 of the woman’s natural cycle (i.e. the first day of her menstrual bleeding).
S uzimanjem tableta treba početi prvog dana ženina prirodnog ciklusa (tj. prvog dana menstrualnog krvarenja).
tablets
tableta
Tablets
Tablete.
tablets (multipack) 126 (9 x 14)
(višestruko pakiranje) 126(9x14) tableta
tablets 4 tablets
tablete 4 tablete
Tablets 90 tablets
Tablete 90 tableta
Tablets also contain the following ingredients Sucrose
Tablete također sadrže sljedeće sastojke: Sukroza
Tablets are engraved with “nGL” on one side and the strength of the tablet on the other.
Tablete imaju utisnutu oznaku "nGL" s jedne strane te jačinu tablete s druge strane.
Tablets are round, beige to brown, non-divisible and with imprints “NA” on one side and “AK” on the other side.
Okrugle, bež do smeđe tablete, bez razdjelne crte, s utisnutom oznakom „NA“ na jednoj strani i „AK“ na drugoj strani.
Tablets are round, slightly biconvex, slightly yellow tablets with possible individual yellow spots.
Tablete su okrugle, blago bikonveksne, svijetlo žute s mogućim pojedinačnim žutim mrljama.
Tablets are round, slightly biconvex, yellow marbled tablets with possible individual spots.
Tablete su okrugle, blago bikonveksne, žute, mramorirane tablete s mogućim pojedinačnim mrljama.
Tablets are yellow, oval-shaped, film-coated tablets, size 8.48 mm x 4.76 mm, with “351” on one side and the MSD logo on the other side.
Tablete su žute, ovalne, filmom obložene tablete veličine 8,48 mm x 4,76 mm, s oznakom "351 " na jednoj i logotipom tvrtke MSD na drugoj strani.
Tablets available in aluminum foil blisters.
Tablete su dostupne u blisterima od aluminijske folije.
Tablets must be chewed and taken with meals.
Tablete se moraju žvakati i uzimati uz obroke.
Tablets must only be given if the child is able to swallow tablets.
Tablete se smiju davati samo ako ih dijete može progutati.
Tablets packaged in:
Tablete zapakirane u:
Tablets per dose
Tablete po dozi
tablets should be increased to 500/125 mg twice daily when co-administered with efavirenz 600 mg once daily.
Dozu lopinavir/ritonavir tableta mora se povisiti na 500/125 mg dvaput na dan kada se primjenjuju istodobno s efavirenzom u dozi od 600 mg jedanput na dan.
Tablets should be kept in the blister package until administration.
Tablete je do primjene potrebno čuvati u blister pakiranju.
Tablets should be kept in the blister packs until required and the blisters should be kept in the carton.
Držite tablete u blisteru do trenutka primjene i čuvajte blistere u pripadajućoj kartonskoj kutijici.
Tablets should be swallowed whole with a glass of water (180 to 240 ml) while the patient is sitting or standing in an upright position.
Tablete treba progutati cijele uz čašu vode (180 do 240 ml) dok bolesnik stoji ili sjedi u uspravnom položaju.
Tablets should be swallowed whole with a glass of water (180 to 240 ml) while the patient is sitting or standing in an upright position.
Tabletu treba progutati cijelu uz čašu obične vode (180 do 240 ml) dok bolesnik stoji ili sjedi u uspravnom položaju.
Tablets should be swallowed without chewing with a glass of water.
Tablete treba progutati bez žvakanja, uz čašu vode.
Tablets should be taken whole and not divided.
Tablete treba uzeti cijele, ne smiju se prepoloviti.
tablets(multipack)
tableta
tablets)
obloženih tableta)
tablets)
tableta)
Tablets’ core
Jezgra tableta
Tablulated list of adverse reactions in head and neck cancer for Docetaxel 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za Docetaksel 75 mg/m2 u kombinaciji s cisplatinom i 5-fluorouracilom za terapiju karcinoma glave i vrata
Tablulated list of adverse reactions in prostate cancer for Docetaxel 75 mg/m² in combination with prednisone or prednisolone
Tablični popis nuspojava kod karcinoma prostate za Docetaksel 75 mg/m² u kombinaciji s prednizonom ili prednizolonom
Tabular Listing of adverse events:
Tablični pregled nuspojava:
Tabulated information on dosing by body weight of patient.
Tabelirane informacije o doziranju prema tjelesnoj težini bolesnika.
Tabulated list of ADRs
Tablični popis nuspojava
Tabulated list of adverse drug reactions
Tablični popis nuspojava na lijek
Tabulated list of adverse drug reactions
Tablični prikaz nuspojava
Tabulated list of adverse reaction
Tablični popis nuspojava
Tabulated list of adverse reactions
Popis pomoćnih tvari
Tabulated list of adverse reactions
Sažetak nuspojava u tablici
Tabulated list of adverse reactions
Tablica nuspojava
Tabulated list of adverse reactions
Tablični prikaz nuspojava:
Tabulated list of adverse reactions for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer – pooled data
Tablični popis nuspojava za adjuvantno liječenje za Docetaksel 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions for adjuvant therapy with Docetaxel Winthrop 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tablični popis nuspojava za adjuvantno liječenje za Docetaxel Winthrop 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions for adjuvant therapy with TAXOTERE 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tablični popis nuspojava za adjuvantno liječenje za TAXOTERE 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions for RCC and DTC studies
Tablični popis nuspojava u ispitivanjima karcinoma bubrežnih stanica i diferenciranog karcinoma štitnjače
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with docetaxel 75 mg/m2 in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tablični popis nuspojava za adjuvantno liječenje za Docetaxel 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data.
Tablični popis nuspojava za adjuvantno liječenje docetakselom 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data.
Tablični popis nuspojava za adjuvantno liječenje za docetakselom 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer – pooled data
Tablični popis nuspojava za adjuvantno liječenje za Docetaksel 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with DOCETAXEL KABI 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tablični popis nuspojava za adjuvantno liječenje za DOCETAXEL KABI 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with Taxespira 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tablični popis nuspojava za adjuvantno liječenje za Taxespira 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with TAXOTERE 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Tablični popis nuspojava za adjuvantno liječenje za TAXOTERE 75 mg/m2 u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima – skupni podaci
Tabulated list of adverse reactions in breast cancer for Docetaxel 100 mg/m2 in combination with trastuzumab
Tablični popis nuspojava kod karcinoma dojke za Docetaxel 100 mg/m² u kombinaciji s trastuzumabom
Tabulated list of adverse reactions in breast cancer for Docetaxel 100 mg/m2 single agent
Tablični popis nuspojava kod karcinoma dojke za Docetaxel 100 mg/m² u monoterapiji
Tabulated list of adverse reactions in breast cancer for Docetaxel 100 mg/m² single agent:
Tablični popis nuspojava kod karcinoma dojke za docetaksel 100 mg/m² u monoterapiji
Tabulated list of adverse reactions in breast cancer for Docetaxel 75 mg/m2 in combination with capecitabine
Tablični popis nuspojava kod karcinoma dojke za Docetaxel 75 mg/m² u kombinaciji s kapecitabinom
Tabulated list of adverse reactions in breast cancer for Docetaxel 75 mg/m2 in combination with doxorubicin
Tablični popis nuspojava kod karcinoma dojke za Docetaxel 75 mg/m² u kombinaciji s doksorubicinom
Tabulated list of adverse reactions in breast cancer for Docetaxel 75 mg/m² in combination with doxorubicin
Tablični popis nuspojava kod karcinoma dojke za docetaksel 75 mg/m² u kombinaciji s doksorubicinom
Tabulated list of adverse reactions in breast cancer for DOCETAXEL KABI 100 mg/m² in combination with trastuzumab
Tablični popis nuspojava kod karcinoma dojke za DOCETAXEL KABI 100 mg/m² u kombinaciji s trastuzumabom.
Tabulated list of adverse reactions in breast cancer for DOCETAXEL KABI 100 mg/m² single agent
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za DOCETAXEL KABI 100 mg/m² u monoterapiji
Tabulated list of adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m² in combination with trastuzumab
Tablični popis nuspojava kod karcinoma dojke za Docetaxel Winthrop 100 mg/m² u kombinaciji s trastuzumabom
Tabulated list of adverse reactions in breast cancer for Docetaxel Winthrop 75 mg/m² in combination with capecitabine
Tablični popis nuspojava kod karcinoma dojke za Docetaxel Winthrop 75 mg/m² u kombinaciji s kapecitabinom
Tabulated list of adverse reactions in breast cancer for Docetaxel Winthrop 75 mg/m² in combination with doxorubicin
Tablični popis nuspojava kod karcinoma dojke za Docetaxel Winthrop 75 mg/m² u kombinaciji s doksorubicinom
Tabulated list of adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za Docetaxel 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Tabulated list of adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75 mg/m² in combination with cisplatin and 5-fluorouracil:
Tablični popis nuspojava za Docetaksel 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Tabulated list of adverse reactions in gastric adenocarcinoma cancer for Docetaxel Winthrop 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za Docetaxel Winthrop 75 mg/m² u kombinaciji s cisplatinom i 5- fluorouracilom u terapiji adenokarcinoma želuca
Tabulated list of adverse reactions in gastric adenocarcinoma cancer for TAXOTERE 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za TAXOTERE 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Tabulated list of adverse reactions in gastric adenocarcinoma center for DOCETAXEL KABI 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za DOCETAXEL KABI 75 mg/m² u kombinaciji s cisplatinom i 5- fluorouracilom u terapiji adenokarcinoma želuca
Tabulated list of adverse reactions in gastric adenocarcinoma center for TAXOTERE 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za TAXOTERE 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Tabulated list of adverse reactions in head and neck cancer for Docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za Docetaxel 75 mg/m2 u kombinaciji s cisplatinom i 5-fluorouracilom za terapiju karcinoma glave i vrata
Tabulated list of adverse reactions in head and neck cancer for DOCETAXEL KABI 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za DOCETAXEL KABI 75 mg/m2 u kombinaciji s cisplatinom i 5- fluorouracilom za terapiju karcinoma glave i vrata
Tabulated list of adverse reactions in head and neck cancer for Docetaxel Winthrop 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za Docetaxel Winthrop 75 mg/m2 u kombinaciji s cisplatinom i 5- fluorouracilom za terapiju karcinoma glave i vrata
Tabulated list of adverse reactions in head and neck cancer for Taxespira 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za Taxespira 75 mg/m2 u kombinaciji s cisplatinom i 5-fluorouracilom za terapiju karcinoma glave i vrata
Tabulated list of adverse reactions in head and neck cancer for TAXOTERE 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za TAXOTERE 75 mg/m2 u kombinaciji s cisplatinom i 5-fluorouracilom za terapiju karcinoma glave i vrata
Tabulated list of adverse reactions in non-small cell lung cancer for Docetaxel 75 mg/m2 in combination with cisplatin
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za Docetaxel 75 mg/m² u kombinaciji s cisplatinom
Tabulated list of adverse reactions in non-small cell lung cancer for Docetaxel 75 mg/m2 single agent
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za Docetaxel 75 mg/m² u monoterapiji
Tabulated list of adverse reactions in non-small cell lung cancer for Docetaxel 75 mg/m² in combination with cisplatin
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za docetaksel 75 mg/m² u kombinaciji s cisplatinom
Tabulated list of adverse reactions in non-small cell lung cancer for Docetaxel 75 mg/m² single agent
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za docetaksel 75 mg/m² u monoterapiji
Tabulated list of adverse reactions in non-small cell lung cancer for DOCETAXEL KABI 75 mg/m² single agent
Tablični popis nuspojava kod karcinoma dojke za DOCETAXEL KABI 75 mg/m² u monoterapiji
Tabulated list of adverse reactions in non-small cell lung cancer for Docetaxel Winthrop 75 mg/m² in combination with cisplatin
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za Docetaxel Winthrop 75 mg/m² u kombinaciji s cisplatinom
Tabulated list of adverse reactions in non-small cell lung cancer for Docetaxel Winthrop 75 mg/m² single agent
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za Docetaxel Winthrop 75 mg/m² u monoterapiji
Tabulated list of adverse reactions in non-small cell lungcancer for DOCETAXEL KABI 75 mg/m² single agent
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za DOCETAXEL KABI 75 mg/m² u monoterapiji
Tabulated list of adverse reactions in non-small lung cancer for DOCETAXEL KABI 75 mg/m² in combination with cisplatin
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za DOCETAXEL KABI 75 mg/m² u kombinaciji s cisplatinom
Tabulated list of adverse reactions in non-small lung cancer for DOCETAXEL KABI 75 mg/m² single agent
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za DOCETAXEL KABI 75 mg/m² u monoterapiji
Tabulated list of adverse reactions in prostate cancer for Docetaxel 75 mg/m2 in combination with prednisone or prednisolone
Tablični popis nuspojava kod karcinoma prostate za Docetaxel 75 mg/m² u kombinaciji s prednizonom ili prednizolonom
Tabulated list of adverse reactions in prostate cancer for Docetaxel 75 mg/m² in combination with prednisone or prednisolone
Tablični popis nuspojava kod karcinoma prostate za docetaksel 75 mg/m² u kombinaciji s prednizonom ili prednizolonom
Tabulated list of adverse reactions in prostate cancer for Docetaxel Winthrop 75 mg/m² in combination with prednisone or prednisolone
Tablični popis nuspojava kod karcinoma prostate za Docetaxel Winthrop 75 mg/m² u kombinaciji s prednizonom ili prednizolonom
Tabulated list of adverse reactions in prostate cancer for TAXOTERE 75 mg/m² in combination with prednisone or prednisolone
Tablični popis nuspojava kod karcinoma prostate za TAXOTERE 75 mg/m² u kombinaciji s prednizonom ili prednizolonom
Tabulated list of adverse reactions in prostatecancer for DOCETAXEL KABI 75 mg/m² in combination with prednisone or prednisolone
Tablični popis nuspojava kod karcinoma prostate za DOCETAXEL KABI 75 mg/m² u kombinaciji s prednizonom ili prednizolonom
Tabulated list of adverse reactions to gastric adenocarcinoma cancer for Docetaxel 75 mg/m² in combination with cisplatin and 5-fluorouracil
Tablični popis nuspojava za Docetaksel 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Tabulated list of adverse reactions – fosaprepitant
Tablični popis nuspojava - fosaprepitant
Tabulated list of adverse reactions#
Tablični popis nuspojava #